awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26786618-0323B40C-8BE2-4E34-8A07-D4C812DD2889
Q26786618-0323B40C-8BE2-4E34-8A07-D4C812DD2889
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26786618-0323B40C-8BE2-4E34-8A07-D4C812DD2889
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
P2860
Q26786618-0323B40C-8BE2-4E34-8A07-D4C812DD2889
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26786618-0323B40C-8BE2-4E34-8A07-D4C812DD2889
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
54f6c0ec189e45d089132377e86eda71e70ed37a
P2860
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.